UNSPSC 51381502: Etofenamate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C18H18F3NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KZF0XM66JC, chemically known as 2-(2-hydroxyethoxy)ethyl-n-(alpha,alpha,alpha-trifluoro-m-tolyl)anthranilate but generally known as etofenamate, which bears US NIH Compound Identifier 35375. European Medicines Agency schedules Etofenamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07319MIG.

UNSPSC 51381502 Etofenamate is a Commodity code that, based on recent state and local procurement activity, designates pharmaceutical products for community health and public health emergency response. The code shows limited recent solicitation activity; the only available recent opportunity is a Seminole County, Florida IFB for naloxone and drug deactivation systems, which diverges from the code's nominal scope of etofenamate (a nonsteroidal anti-inflammatory drug) and does not represent typical purchasing under this classification. State and local governments soliciting under this code appear to include county health departments and community health organizations focused on public health initiatives, particularly opioid-response programs. The solicitations typically require competitive bidding with fixed-fee pricing structures, electronic submission through local e-procurement portals, standard contractor certifications (drug-free workplace, E-Verify compliance), and insurance requirements including workers' compensation and commercial general liability.

Recent activity centers in Florida, specifically Seminole County. Seminole County's IFB 60459723LAS, posted June 30, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023 at 2:00 pm. The contract included a two-year initial term with a one-year renewal option and potential FEMA funding, triggering additional federal compliance requirements. The procurement does not specify set-aside designations for disadvantaged enterprises. Given the sparse recent-opportunity data and the mismatch between the code's pharmaceutical classification and the naloxone-focused solicitation retrieved, this code shows minimal demonstrable activity in the current state and local procurement marketplace.